

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)



(10) International Publication Number
WO 2023/118085 A1

(51) International Patent Classification:

A61K 31/336 (2006.01) A61K 45/06 (2006.01)
A61K 31/495 (2006.01) A61P 35/00 (2006.01)
A61K 31/498 (2006.01) A61K 41/00 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/EP2022/086913

(22) International Filing Date:

20 December 2022 (20.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/292,029 21 December 2021 (21.12.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).

(72) Inventor: **HAMERLIK, Petra**; AstraZeneca UK Limited,
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge, Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Eastbrook House, Shaftesbury Road, Cambridge, Cam-
bridgeshire, CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS

(57) Abstract: The present disclosure relates to methods of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a substituted azaquinolone compounds having activity as a poly(ADP-ribose) polymerase (PARP) inhibitor.



WO 2023/118085 A1